Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Pembrolizumab
Indication/Tumor Type bladder urothelial carcinoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive bladder urothelial carcinoma sensitive Pembrolizumab Phase II Actionable In a Phase II clinical study (PURE-01), neoadjuvant Keytruda (pembrolizumab) treatment in patients with muscle invasive bladder cancer with CD274 (PD-L1) combined positive scores greater than or equal to 10% resulted in a 54.3% (19/35) complete pathological response at resection compared to a 13.3% (2/15) complete pathological response at resection in patients with CD274 (PD-L1) CPS less than 10% (PMID: 30343614; NCT02736266). 30343614
CD274 positive bladder urothelial carcinoma sensitive Pembrolizumab Phase II Actionable In a Phase II (KEYNOTE-052) trial, Keytruda (pembrolizumab) treatment resulted in objective response in 24% (89/370) of cisplatin-ineligible patients with urothelial cancer, patients with an expression of CD274 (PD-L1) over 10% demonstrated improved response, with an objective response rate of 38% (42/110) (PMID: 28967485; NCT02335424). 28967485
PubMed Id Reference Title Details
(28967485) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Full reference...
(30343614) Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Full reference...